Savara, PARI Granted European Patent Titled 'Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.'

"This patent covers our drug-device combination through March 2043," said Matt Pauls, J.D., M.B.A, Chair and Chief Executive Officer, Savara. "With 10 years of Orphan Drug regulatory exclusivity upon EU approval, as well as our exclusive license with PARI, this patent strengthens the long-term protection of MOLBREEVI for the treatment of autoimmune PAP in Europe. As we prepare for a December resubmission of the MOLBREEVI BLA in the U.S. and 1Q 2026 MOLBREEVI MAA submissions in Europe and the U.K., we will continue to pursue additional intellectual property protection in Europe, the U.S., and other major markets."